Endoscopic "Push-Trough" Technique Cartilage Myringoplasty in Anterior Tympanic Membrane Perforations

ObjectivesTo evaluate endoscopic push-through technique cartilage myringoplasty results.MethodsThis prospective study was performed on patients with anterior tympanic membrane perforations and endoscopic push-through technique cartilage myringoplasty was performed between 2011 and 2013. The patients who did not have any cholesteatoma or otorrhea in the previous 3 months, and had an air bone gap ≤25 dB in their preoperative audiograms were included in the study. They were followed up with endoscopic examination and audiograms at 2nd, 6th, 12th, and 24th postoperative months. Pure tone averages were calculated at 0.5, 1, 2, and 4 kHz frequencies.ResultsOf 32 patients, 19 were females and 13 were males. The mean age was 40.3 years (range, 16 to 62 years), and the mean follow-up period was 12.4 months (range, 6 to 24 months). Graft success rate was 87.5% in this study. Preoperative mean air conduction hearing threshold was 25.9 dB, and the mean air-bone gap was 11.9 dB while these values improved to 19.5 dB and 5.3 dB respectively in the postoperative period. The mean hearing gain was 6.4 dB. The analysis of preoperative and postoperative mean air conduction thresholds and air bone gap values of the patients revealed statistically significant differences.ConclusionUnderlay cartilage myringoplasty with endoscopic push-through technique in anterior quadrant tympanic membrane perforations is an effective, minimally invasive and feasible method

The Effect of Proton-Pump Inhibitors on the Frequency and the Course of the Community Acquired Pneumonia

Objective: Proton pump inhibitors (PPIs) are the primary drugs with proven efficacy in gastrointestinal diseases. The effectiveness of these drugs causes unneccessary use and potential risks. The aim of the study was to evaluate the rates of PPI use and its effect on the course of the disease in patients with community aqcuired pneumonia (CAP). Methods: The patients who were hospitalized due to pneumonia were asked about the use of PPIs, whether they were a current user, user in the last 3 months or never used. The rates of PPI use and the effect of PPI use on clinical and radiological improvement, duration of treatment and hospitalization, development of complication, need of intensive care unit and mortality were evaluated. Results: Sixty-eight patients were included in the study. The mean age of patients was 70.7 +/- 12.5 years. The rates of PPI use (current use, use in 3 months and never used) were as follows: 39%, 11.8% and 48.5% respectively. The duration of treatment and hospitalization, duration of clinical and radiological improvement were found longer in patients who were using PPI currently compared to never used (respectively; p=0.08, p=0.024, p=0.007, p=0.016). The rate of complications was higher in the current users than never users (14.8% vs 6.1%). Conclusion: Thirty-nine percent of the patients with CAP were using PPI currently. The course of pneumonia was more severe in this group. The unneccessary use of PPIs should be avoided in order to decrease the incidence and morbidity of CAP

Investigation of the beta 2-adrenoceptor (ADRB2) 16 and glutathione S-transferase P1 (GSTP1) gene polymorphisms in Turkish asthma patients

WOS: 000250273700373

PLASMA NITRIC OXIDE LEVELS AND NITRIC OXIDE SYNTHASE ACTIVITY IN LUNG CANCER PATIENTS

GURBUZ, ASLIHAN/0000-0002-5089-3965WOS: 000264089500345

The effect of CYP1A1, GSTT1 and GSTM1 polymorphisms on the risk of lung cancer: A case-control study

ATINKAYA, CANSEL/0000-0002-8583-3479WOS: 000309712900010PubMed: 22893352Lung cancer, which is mainly affected by environmental factors, is a lethal malignancy. It is also important to investigate the effect of genetic factors on lung cancer aetiology. In this study, we aimed to investigate the distribution of CYP1A1*2C, GSTT1 and GSTM1 polymorphisms in Turkish lung cancer patients to determine whether any promoting effect of polymorphisms could cause development of lung cancer. For this purpose, genomic DNA samples obtained from peripheral blood of 128 patients with lung cancer and 122 healthy subjects were analyzed. Genotyping of polymorphic enzymes were carried out by polymerase chain reaction-restriction fragment length polymorphism methods. Although there were no significant differences between groups in terms of CYP1A1 polymorphism, the carriers of CYP1A1 Ile/Val genotype (odds ratio [OR] = 1.224, 95% confidence interval [CI]: 0.585-2.564) or CYP1A1 Val/Val genotype (OR = 3.058, 95% CI: 0.312-30.303) had an increased risk of lung cancer development. There was no statistical difference between groups in terms of both GSTT1 null genotype (OR = 1.114, 95% CI: 0.590-2.105) and GSTM1 null genotype (OR = 0.776, 95% CI: 0.466-1.290). This is the first case-control study investigating CYP1A1 Ile/Val, GSTT1 and GSTM1 polymorphisms in Turkish lung cancer patients. Although we suggest that other genes in addition to the proposed genes could play a role in lung cancer development, the results of our study will contribute to the possible associations between CYP1A1 Ile/Val, GSTT1 and GSTM1 gene polymorphism on the risk of lung cancer

PLASMA ADA AND PON1-ARYLESTERASE ENZYME ACTIVITIES IN LUNG CANCER PATIENTS

GURBUZ, ASLIHAN/0000-0002-5089-3965WOS: 000264089500214